DK2275103T3 - mTor-inhibitorer ved behandling af endokrine tumorer - Google Patents

mTor-inhibitorer ved behandling af endokrine tumorer

Info

Publication number
DK2275103T3
DK2275103T3 DK10175197.2T DK10175197T DK2275103T3 DK 2275103 T3 DK2275103 T3 DK 2275103T3 DK 10175197 T DK10175197 T DK 10175197T DK 2275103 T3 DK2275103 T3 DK 2275103T3
Authority
DK
Denmark
Prior art keywords
treatment
mtor inhibitors
endocrine tumors
endocrine
tumors
Prior art date
Application number
DK10175197.2T
Other languages
English (en)
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2275103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2275103T3 publication Critical patent/DK2275103T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10175197.2T 2005-11-21 2006-11-20 mTor-inhibitorer ved behandling af endokrine tumorer DK2275103T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14
EP08162295A EP2022498A3 (en) 2005-11-21 2006-11-20 Neuroendocrine tumour treatment

Publications (1)

Publication Number Publication Date
DK2275103T3 true DK2275103T3 (da) 2014-07-07

Family

ID=37671355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10175197.2T DK2275103T3 (da) 2005-11-21 2006-11-20 mTor-inhibitorer ved behandling af endokrine tumorer

Country Status (22)

Country Link
US (3) US9006224B2 (da)
EP (3) EP2022498A3 (da)
JP (3) JP2009516671A (da)
KR (2) KR20080071600A (da)
CN (1) CN103446138A (da)
AU (2) AU2006314444C1 (da)
BR (1) BRPI0618808A2 (da)
CA (2) CA2933875C (da)
CY (1) CY1115299T1 (da)
DK (1) DK2275103T3 (da)
ES (1) ES2481671T3 (da)
HK (1) HK1150746A1 (da)
HR (1) HRP20140708T1 (da)
IL (3) IL191475A (da)
MA (1) MA29966B1 (da)
NO (4) NO346575B1 (da)
NZ (1) NZ568182A (da)
PL (1) PL2275103T3 (da)
PT (1) PT2275103E (da)
RU (1) RU2487711C2 (da)
SI (1) SI2275103T1 (da)
WO (1) WO2007057457A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728739T3 (es) 2001-02-19 2019-10-28 Novartis Pharma Ag Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
CN101415424B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
MX348705B (es) 2008-09-17 2017-06-26 Chiasma Inc Composiciones farmacéuticas y métodos de administración relacionados.
US9057054B2 (en) 2009-06-25 2015-06-16 The Regents Of The University Of Michigan Antigen-specific long-term memory T-cells
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP3466423B1 (en) 2011-10-19 2021-07-28 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
WO2014134240A1 (en) * 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
EP2967059A4 (en) * 2013-03-15 2017-03-22 The Board of Regents of The University of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2017000085A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Sunlidac在制备抗肺癌产品中的应用
MA43800A (fr) * 2016-01-21 2021-05-12 Chiasma Inc Octréotide par voie orale pour le traitement de maladies
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019157363A2 (en) * 2018-02-09 2019-08-15 Mount Tam Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
WO2020191002A1 (en) * 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions and methods for treating cushing's disease
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2022260918A1 (en) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (da) 1992-04-03 1994-06-21 Ciba Geigy Ag
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
DK0817775T3 (da) 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
ES2193379T3 (es) * 1996-06-11 2003-11-01 Novartis Ag Combinacion de un analogo de somatostatina y de una rapamicina.
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US5932613A (en) 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
RU2264405C2 (ru) 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1337527B1 (en) 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
ES2728739T3 (es) * 2001-02-19 2019-10-28 Novartis Pharma Ag Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
CN1309421C (zh) * 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
MXPA03010907A (es) * 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
UA78706C2 (en) 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
NZ540427A (en) 2002-12-09 2008-04-30 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2005064343A1 (en) 2003-12-22 2005-07-14 Novartis Ag Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
WO2005080593A2 (en) * 2004-02-23 2005-09-01 Novartis Ag P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
EP1720574A4 (en) * 2004-02-23 2009-09-09 Sugen Inc METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND M-TOR INHIBITORS
BRPI0515774A (pt) 2004-12-15 2008-08-05 Novartis Ag combinações de agentes terapêuticos para o tratamento de cáncer
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1

Also Published As

Publication number Publication date
JP2009516671A (ja) 2009-04-23
SI2275103T1 (sl) 2014-07-31
CA2933875A1 (en) 2007-05-24
WO2007057457A2 (en) 2007-05-24
NO344288B1 (no) 2019-10-28
KR20140012218A (ko) 2014-01-29
RU2487711C2 (ru) 2013-07-20
JP5963836B2 (ja) 2016-08-03
RU2008124827A (ru) 2009-12-27
JP2013144706A (ja) 2013-07-25
BRPI0618808A2 (pt) 2011-09-13
EP2022498A3 (en) 2012-08-15
CA2629245C (en) 2016-07-12
WO2007057457A3 (en) 2008-01-10
CA2933875C (en) 2018-06-26
AU2010202866A1 (en) 2010-07-29
CA2629245A1 (en) 2007-05-24
HRP20140708T1 (hr) 2014-09-26
MA29966B1 (fr) 2008-11-03
NO20082683L (no) 2008-08-12
JP5833048B2 (ja) 2015-12-16
US20150148294A1 (en) 2015-05-28
HK1150746A1 (en) 2012-01-13
IL191475A (en) 2017-08-31
EP2022498A2 (en) 2009-02-11
AU2006314444A1 (en) 2007-05-24
NZ568182A (en) 2010-08-27
IL250697A0 (en) 2017-04-30
PT2275103E (pt) 2014-07-24
EP2275103A3 (en) 2011-10-12
NO20161045A1 (no) 2008-08-12
NO20170956A1 (no) 2008-08-12
CN103446138A (zh) 2013-12-18
JP2015061868A (ja) 2015-04-02
IL253698A0 (en) 2017-09-28
KR20080071600A (ko) 2008-08-04
ES2481671T3 (es) 2014-07-31
AU2006314444B2 (en) 2010-08-26
NO341023B1 (no) 2017-08-07
EP1954269A2 (en) 2008-08-13
NO346575B1 (no) 2022-10-17
EP2275103A2 (en) 2011-01-19
US20170128425A1 (en) 2017-05-11
CY1115299T1 (el) 2017-01-04
US20080255029A1 (en) 2008-10-16
EP2275103B1 (en) 2014-04-23
AU2006314444C1 (en) 2018-01-04
US9006224B2 (en) 2015-04-14
PL2275103T3 (pl) 2014-09-30
NO20220050A1 (no) 2008-08-12

Similar Documents

Publication Publication Date Title
DK2275103T3 (da) mTor-inhibitorer ved behandling af endokrine tumorer
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2100614T3 (da) Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
DE602005002517D1 (de) Drehtisch
DK1951724T3 (da) Sammensmeltede bicykliske mTOR-inhibitorer
DK1859793T3 (da) Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
DE602005017215D1 (de) Thiadiazolidinone als GSK3-Inhibitoren
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
CY2200156T2 (el) Επεξεργασια λυματων
DE602006019395D1 (de) Media-behandlungseinrichtung
NO20070251A (no) Brønnbehandling
ATE493403T1 (de) Kinaseinhibitoren
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
DK1713805T3 (da) Kinaseinhibitorer
DK1803456T5 (da) Farmaceutiske sammensætninger omfattende L-733060 til anvendelse ved behandling af cancertumorer
FI20040011A (fi) Menetelmä pintojen käsittelemiseksi
ITMO20050254A1 (it) Gruppo abrasivo
DE112005002873A5 (de) Meerwasserentsalzungsanlage
DK1933840T3 (da) Anvendelse af delmopinol i behandlingen af acne
DK1765832T3 (da) Hidtil ukendte oxabispidinforbindelser deres anvendelse til behandling af hjertearytmier
DE602005002391D1 (de) Schwenkbarer Drehtisch
DK2120919T3 (da) Ny kombination til anvendelse ved behandling af inflammatoriske lidelser